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Table 2
Grade 3/4 Non-hematologic Toxicities
Preferred Term All Grades % (N¼61) Grade 3/4 % (N¼61)
Diarrhea 93 3
Nausea 90 2
Fatigue 77 2
Hypokalemia 74 28
Vomiting 64 0
Hypophosphatemia 49 48
Decreased Appetite 49 0
Pyrexia 48 3
Constipation 48 0
Febrile Neutropenia 41 28
Mucosal Inﬂammation 38 10
Dizziness 38 0
Stomatitis 28 5
Abdominal Pain 28 0
Dysgeusia 28 0
Dyspepsia 26 0
Abstracts / Biol Blood Marrow Transplant 21 (2015) S127eS146S138implanted ports and therefore had a Vascath placed on the
morning of pheresis. Twelve patients completed pheresis
and reached target CD34 collection through double lumen
CVL. One patient was unable to complete pheresis via his
CVL and had a successful pheresis the following day after
Vascath placement. Median inlet ﬂow rates were
signiﬁcantly lower in patients undergoing pheresis with a
double lumen CVL when compared to patients undergoing
pheresis via Vascath and there was a signiﬁcantly higher
rate of pressure error readings in patients with CVLs. Time
from admission to start of pheresis was signiﬁcantly less in
patients who underwent pheresis with a CVL. There was no
signiﬁcant difference in time on machine, CD34/kg
collected, or number of days of pheresis.
Conclusion: Hematopoietic stem cell pheresis utilizing dou-
ble lumenCVL is feasiblewith the potential beneﬁts of shorter
hospitalization and avoidance of second line placement.155
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Melphalan 200 mg/m2 IV is the most common conditioning
regimen for AHCT in MM. Conventional melphalan formu-
lations (eg, Alkeran) have marginal solubility, limited
chemical stability and require PG as a co-solvent, which is
associated with renal dysfunction and arrhythmias. Captisol-
enabled Melphalan HCL (CE-Melphalan) is a PG-free formu-
lation of melphalan that incorporates Captisol, a modiﬁedTable 1
Patient Characteristics
Total (N[61)
Median Age (range) in yrs 62 (32-73)
Age ‡ 65 yrs 30%
Male Gender 57%
Race
White 80%
Black/African American 18%
Other 2%
ECOG Status
0 59%
1 38%
2 3%
Disease Status Pre-treatment
sCR 0%
CR 5%
VGPR 44%
PR 32%
Disease Status at Day 100 post-AHCT
sCR 13%
CR 8%
VGPR 61%
PR 18%cyclodextrin that improves its solubility, stability and
bioavailability. In a previous Phase 2 study, CE-Melphalan
was shown to be bioequivalent to Alkeran.
Methods: This Phase II, open-label study enrolled 61 pts with
MMwho received 200 mg/m2 of CE-Melphalan (100 mg/m2/
day x 2) followed by AHCT. Most subjects were male (57%)
with a median age of 62.0 years (range 32-73), including 56
(92%) subjects who received upfront AHCT and 5 (8%) after
relapse (Table 1). Median lines of prior therapy was 3 (range
2-16). High risk cytogenetics in 6 (10%) pts. Disease status at
pre-treatment included CR in 3 subjects, VGPR in 27 and PR
in 20 subjects.
Results: All subjects achieved myeloablation followed by
successful engraftment. Median time to neutrophil engraft-
ment was 12 days post-AHCT (range: 10-12); time to platelet
engraftment was 13 days (range 10-28). There was no mor-
tality by Day 100, and as expected the most common Grade 3
and 4 toxicities were hematologic. Non-hematologic toxic-
ities are summarized in Table 2. Severe mucositis was
reported in few patients (Grade 3/4; 10%). At Day 100 post-
AHCT, all patients (100%) had a response with 82% of subjects
achieving a>¼ VGPR response including sCR in 13%, CR in 8%
and VGPR in 61%.
Conclusions: CE-Melphalan led to successful myeloablation
and subsequent engraftment inMMpatients with nomortality
or unexpected transplant-related toxicity over conventional
melphalan. The incidence of Grade 3-4 mucositis was low.
Overall,100% of subjects responded to high doseCE-Melphalan,
and in the subgroup of high risk patients (n¼6, 10%), an
encouraging 67% VGPR or better responses were achieved.156
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In the post combination antiretroviral therapy (cART) era,
HIV infected patients are better able to tolerate chemo-
therapy for HIV-associated lymphoma and results of the
treatment are similar now to non-HIV infected patients.
Consequently the use of hematopoietic stem cell trans-
plant (HSCT) has been investigated in the post cART era.
One of the main challenges that faces clinicians though is
the potential for cART and chemotherapy drug-drug
interactions.
